26807-73-8

Basic information

• Product Name: 1-BENZYL-1H-INDOL-5-YLAMINE
• Synonyms: 1-BENZYL-1H-INDOL-5-YLAMINE;1-benzyl-1H-indol-5-amine
• CAS NO: 26807-73-8
• Molecular Formula: C₁₅H₁₄N₂
• Molecular Weight: 222.29
• Mol File: 26807-73-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 447°Cat760mmHg
• Flash Point: 224.1°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 3.48E-08mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-BENZYL-1H-INDOL-5-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-1H-INDOL-5-YLAMINE(26807-73-8)
• EPA Substance Registry System: 1-BENZYL-1H-INDOL-5-YLAMINE(26807-73-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 26807-73-8(Hazardous Substances Data)

Usage

General Description

1-Benzyl-1H-indol-5-ylamine is a chemical compound with a molecular formula C20H17N. It is a derivative of indole and contains a benzylamine group attached to the indole nitrogen atom. This chemical has potential biological activity and has been studied for its potential use in pharmaceuticals and medicinal chemistry. It may have applications in the development of new drugs for various purposes, including the treatment of neurological disorders, cancer, and other diseases. Further research is needed to fully understand the properties and potential therapeutic uses of 1-Benzyl-1H-indol-5-ylamine.

InChI:InChI=1/C15H14N2/c16-14-6-7-15-13(10-14)8-9-17(15)11-12-4-2-1-3-5-12/h1-10H,11,16H2

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 65795-95-1 1-benzyl-5-nitro-1H-indole 
• 92433-38-0 1-benzyl-5-chloro-1H-indole 
• 6146-52-7 5-nitroindole 

Downstream Products

• 202272-97-7 (1-Benzyl-1H-indol-5-yl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine 
• 1629161-00-7 2-[(1-benzyl-1H-indol-5-yl)amino]-6-methyl-5-phenylnicotinonitrile 

Relevant articles and documents

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach

Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting Her2 which can be used in clinical routine are lacking, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds, which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion parameters as well as mass spectrometry experiments and western blot analysis substantiated our approach.

Assembly of Primary (Hetero)Arylamines via CuI/Oxalic Diamide-Catalyzed Coupling of Aryl Chlorides and Ammonia

A general and practical catalytic system for aryl amination of aryl chlorides with aqueous or gaseous ammonia has been developed, with CuI as the catalyst and bisaryl oxalic diamides as the ligands. The reaction proceeds at 105-120°C to provide a diverse set of primary (hetero)aryl amines in high yields with various functional groups.

CYANOQUINOLINE DERIVATIVES

Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.